Skip to main content

Time in Range News

Time in Range (TIR) is the percentage of time that a person spends with their blood glucose levels in the target range, usually between 70 and 180 mg/dl.

What’s an AGP report, and what does it show? Why does my AGP matter? How can I use an AGP report to improve my blood glucose levels and time in range?
The Association of Diabetes Care and Education Specialists' 2020 conference covered how to use CGM to adjust insulin during exercise, how to reduce fear of hypoglycemia...
Diabetes and heart disease are closely connected. This article discusses heart disease, important numbers to know, and ways to improve your heart health
En el Mes Nacional de la Salud de las Minorías, el autor comparte la historia de su diagnóstico de diabetes tipo 2
A summary of the landmark trials that show that careful blood glucose management can lower the risk of long-term health complications in people with type 1 or type 2...
Enroll in Level2 to get a CGM, a Fitbit activity tracker, and easily accessible virtual health coaching; the program is designed to help people achieve type 2 diabetes...
Health Canada authorizes the latest temporary approval for CGM during the pandemic: the Dexcom G6 is now available to pregnant women with diabetes
We interviewed Dr. Partha Kar to learn about how people are using time in range in his clinic and what obstacles our society will need to overcome to promote wider use...
Dr. Anne Peters shares insights on how healthcare professionals can help people ease the challenges of managing diabetes during COVID and how the shift to telemedicine...
dQ&A surveyed 2,540 CGM users with type 1 or type 2 diabetes to find out how aware they are of their own time in range: 87% of respondents knew how much time they...
The G6 Pro includes several exciting new features and is expected to start shipping next week!
In exciting news, Tandem announced expanded clearance for the hybrid closed loop Control-IQ. The system is now available for children ages 6-13
The ADA Scientific Sessions starts later this week – we've highlighted some of the most important presentations and posters for you to look forward to
Mark Harmel, a Diabetes Care and Education Specialist, discusses the value of CGM reports, specifically the Glucose Management Indicator (GMI) and time in range (TIR)
Major milestones in 2019 brought time in range to the forefront of diabetes care
In-person visits, lab tests, and finger stick documentation are no longer required at present to get a CGM
Expert physicians share a few of the benefits of virtual appointments for people living with diabetes
Rybelsus, a GLP-1 agonist pill already approved in Europe and the US, has just been approved by Health Canada for adults with type 2 diabetes
Dr. Diana Isaacs on improving time in range, making the most of your data, and the barriers facing people with diabetes and their healthcare teams
Rybelsus, a GLP-1 agonist pill already approved in the US, received positive feedback from the European Medicines Agency (EMA) in January and was just approved on...

Pages